Review



anti phos chk2 t68  (Cell Signaling Technology Inc)


Bioz Verified Symbol Cell Signaling Technology Inc is a verified supplier
Bioz Manufacturer Symbol Cell Signaling Technology Inc manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 96

    Structured Review

    Cell Signaling Technology Inc anti phos chk2 t68
    Anti Phos Chk2 T68, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1458 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti phos chk2 t68/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1458 article reviews
    anti phos chk2 t68 - by Bioz Stars, 2026-03
    96/100 stars

    Images



    Similar Products

    93
    Thermo Fisher rabbit anti phospho thr383 chk2
    (A ) Schematic of the conventional mode of Ca 2+ -CaM activation in members of the Ca 2+ -CaM-dependent protein kinase (CaMK) family. Upon Ca 2+ influx, Ca 2+ -CaM binds a linear sequence (CaM-binding sequence; CaMBS; orange) that is proximal to the CaMK kinase domain (blue). This interaction restores activity by sequestering an autoinhibitory pseudosubstrate sequence, which formerly obstructed the active site. ( B ) Far Western blots show that recombinant full-length <t>CHK2</t> and positive control kinase, CaMKK2, interact with His 6 -CaM in a Ca 2+ -dependent manner (Ca 2+ : 500 μM), as binding is abolished in the presence of the Ca 2+ -chelator, EGTA (10 mM). A negative control pseudokinase, MLKL, did not detectably bind CaM. CaM interaction was detected using an anti-His 6 HRP antibody. data are representative of two independent replicates. ( C ) CHK2 is inhibited by Ca 2+ -CaM. Full-length wildtype and K249A kinase-dead CHK2 were immunoprecipitated and activity was measured by radiometric assay containing 200 μM CHKtide, 200 μM [ 32 P]-γ-ATP and in the presence (red) or absence (white) of 200 μM CaCl 2 , 1 mM CaM for 10 min. Two-way ANOVA; **** P <0.0001; n.s = non-significant. ( D ) Double referenced SPR sensorgrams for immobilised full-length CHK2 binding to analyte, Ca 2+ -CaM. Shown is a representative sensorgram that is colour-coded based on CaM concentration. ( E ) Steady state analysis for the SPR experiment shown in ( D ), along with the dissociation constant. ( F ) Titration of CaM (range 0, 0.5, 1, 2, 5, 10, 20, 50, 100, 200 μM) using immunoprecipitated full-length CHK2 (~10 ng) in the presence of 1 mM CaCl 2 by radiometric assay. The half-maximal inhibitory concentration (IC 50 ) for CaM is 8.1 μM. Data represent mean ± SD; n = 3. ( G ) Plot of highest and lowest CHK2 kinase activity from CaM titration the presence of 1 mM CaCl 2 . Individual data points are shown as circles with accompanying mean ± SD; n = 3. Statistical analysis was performed by unpaired t-test; **** P <0.0001. ( H ) Titration of CaCl 2 (range 0, 1, 2, 5, 10, 20, 50, 100, 200, 500, 1000 μM) using immunoprecipitated full-length CHK2 (~10 ng) in the presence of 200 μM CaM by radiometric assay. the IC 50 of CHK2 and CaM by Ca 2+ is 30.7 μM. Data represent mean ± SD; n = 3. ( I ) Plot of highest and lowest CHK2 kinase activity from CaCl 2 titration in the presence of 200 μM CaM. individual data points are shown as circles with accompanying mean ± SD; n = 3. Statistical analysis was performed by unpaired t-test; *** P <0.001. ( J ) Schematic of the amino acid residues of recombinant full-length CHK2 and CaM (red) chemically cross-linked by DMTMM (‘zero-length’) and ( K ) photoactivatable cross-linker, NHS-Diazarine (SDA; 3.9 Å spacer), following mass-spectrometry analysis. Cross-links (grey) are only observed within the CHK2 kinase domain (blue) for both chemical cross-linkers. ( L ) Six lysine residues in CHK2, identified by DMTMM chemical cross-linking are mapped to the domain architecture of CHK2. ( M ) Radiometric assay of immunoprecipitated CHK2 wildtype and select cross-linked lysine mutants in the presence (red) or absence (white) of 200 μM CaCl 2 , 1 mM CaM for 10 min. Note: wildtype and K249A kinase-dead data are reproduced from ( C ). Data represent mean ± SD; n = 3. Statistical analysis was performed by two-way ANOVA; * and **** P <0.1 and P <0.0001, respectively; n.s = non-significant. Assay data using recombinant CHK2 kinase domain with each cross-linked lysine mutant are shown in .
    Rabbit Anti Phospho Thr383 Chk2, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti phospho thr383 chk2/product/Thermo Fisher
    Average 93 stars, based on 1 article reviews
    rabbit anti phospho thr383 chk2 - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    93
    MedChemExpress rabbit anti pchk2
    (A ) Schematic of the conventional mode of Ca 2+ -CaM activation in members of the Ca 2+ -CaM-dependent protein kinase (CaMK) family. Upon Ca 2+ influx, Ca 2+ -CaM binds a linear sequence (CaM-binding sequence; CaMBS; orange) that is proximal to the CaMK kinase domain (blue). This interaction restores activity by sequestering an autoinhibitory pseudosubstrate sequence, which formerly obstructed the active site. ( B ) Far Western blots show that recombinant full-length <t>CHK2</t> and positive control kinase, CaMKK2, interact with His 6 -CaM in a Ca 2+ -dependent manner (Ca 2+ : 500 μM), as binding is abolished in the presence of the Ca 2+ -chelator, EGTA (10 mM). A negative control pseudokinase, MLKL, did not detectably bind CaM. CaM interaction was detected using an anti-His 6 HRP antibody. data are representative of two independent replicates. ( C ) CHK2 is inhibited by Ca 2+ -CaM. Full-length wildtype and K249A kinase-dead CHK2 were immunoprecipitated and activity was measured by radiometric assay containing 200 μM CHKtide, 200 μM [ 32 P]-γ-ATP and in the presence (red) or absence (white) of 200 μM CaCl 2 , 1 mM CaM for 10 min. Two-way ANOVA; **** P <0.0001; n.s = non-significant. ( D ) Double referenced SPR sensorgrams for immobilised full-length CHK2 binding to analyte, Ca 2+ -CaM. Shown is a representative sensorgram that is colour-coded based on CaM concentration. ( E ) Steady state analysis for the SPR experiment shown in ( D ), along with the dissociation constant. ( F ) Titration of CaM (range 0, 0.5, 1, 2, 5, 10, 20, 50, 100, 200 μM) using immunoprecipitated full-length CHK2 (~10 ng) in the presence of 1 mM CaCl 2 by radiometric assay. The half-maximal inhibitory concentration (IC 50 ) for CaM is 8.1 μM. Data represent mean ± SD; n = 3. ( G ) Plot of highest and lowest CHK2 kinase activity from CaM titration the presence of 1 mM CaCl 2 . Individual data points are shown as circles with accompanying mean ± SD; n = 3. Statistical analysis was performed by unpaired t-test; **** P <0.0001. ( H ) Titration of CaCl 2 (range 0, 1, 2, 5, 10, 20, 50, 100, 200, 500, 1000 μM) using immunoprecipitated full-length CHK2 (~10 ng) in the presence of 200 μM CaM by radiometric assay. the IC 50 of CHK2 and CaM by Ca 2+ is 30.7 μM. Data represent mean ± SD; n = 3. ( I ) Plot of highest and lowest CHK2 kinase activity from CaCl 2 titration in the presence of 200 μM CaM. individual data points are shown as circles with accompanying mean ± SD; n = 3. Statistical analysis was performed by unpaired t-test; *** P <0.001. ( J ) Schematic of the amino acid residues of recombinant full-length CHK2 and CaM (red) chemically cross-linked by DMTMM (‘zero-length’) and ( K ) photoactivatable cross-linker, NHS-Diazarine (SDA; 3.9 Å spacer), following mass-spectrometry analysis. Cross-links (grey) are only observed within the CHK2 kinase domain (blue) for both chemical cross-linkers. ( L ) Six lysine residues in CHK2, identified by DMTMM chemical cross-linking are mapped to the domain architecture of CHK2. ( M ) Radiometric assay of immunoprecipitated CHK2 wildtype and select cross-linked lysine mutants in the presence (red) or absence (white) of 200 μM CaCl 2 , 1 mM CaM for 10 min. Note: wildtype and K249A kinase-dead data are reproduced from ( C ). Data represent mean ± SD; n = 3. Statistical analysis was performed by two-way ANOVA; * and **** P <0.1 and P <0.0001, respectively; n.s = non-significant. Assay data using recombinant CHK2 kinase domain with each cross-linked lysine mutant are shown in .
    Rabbit Anti Pchk2, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti pchk2/product/MedChemExpress
    Average 93 stars, based on 1 article reviews
    rabbit anti pchk2 - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    95
    Proteintech phospho chk2 t68
    (A ) Schematic of the conventional mode of Ca 2+ -CaM activation in members of the Ca 2+ -CaM-dependent protein kinase (CaMK) family. Upon Ca 2+ influx, Ca 2+ -CaM binds a linear sequence (CaM-binding sequence; CaMBS; orange) that is proximal to the CaMK kinase domain (blue). This interaction restores activity by sequestering an autoinhibitory pseudosubstrate sequence, which formerly obstructed the active site. ( B ) Far Western blots show that recombinant full-length <t>CHK2</t> and positive control kinase, CaMKK2, interact with His 6 -CaM in a Ca 2+ -dependent manner (Ca 2+ : 500 μM), as binding is abolished in the presence of the Ca 2+ -chelator, EGTA (10 mM). A negative control pseudokinase, MLKL, did not detectably bind CaM. CaM interaction was detected using an anti-His 6 HRP antibody. data are representative of two independent replicates. ( C ) CHK2 is inhibited by Ca 2+ -CaM. Full-length wildtype and K249A kinase-dead CHK2 were immunoprecipitated and activity was measured by radiometric assay containing 200 μM CHKtide, 200 μM [ 32 P]-γ-ATP and in the presence (red) or absence (white) of 200 μM CaCl 2 , 1 mM CaM for 10 min. Two-way ANOVA; **** P <0.0001; n.s = non-significant. ( D ) Double referenced SPR sensorgrams for immobilised full-length CHK2 binding to analyte, Ca 2+ -CaM. Shown is a representative sensorgram that is colour-coded based on CaM concentration. ( E ) Steady state analysis for the SPR experiment shown in ( D ), along with the dissociation constant. ( F ) Titration of CaM (range 0, 0.5, 1, 2, 5, 10, 20, 50, 100, 200 μM) using immunoprecipitated full-length CHK2 (~10 ng) in the presence of 1 mM CaCl 2 by radiometric assay. The half-maximal inhibitory concentration (IC 50 ) for CaM is 8.1 μM. Data represent mean ± SD; n = 3. ( G ) Plot of highest and lowest CHK2 kinase activity from CaM titration the presence of 1 mM CaCl 2 . Individual data points are shown as circles with accompanying mean ± SD; n = 3. Statistical analysis was performed by unpaired t-test; **** P <0.0001. ( H ) Titration of CaCl 2 (range 0, 1, 2, 5, 10, 20, 50, 100, 200, 500, 1000 μM) using immunoprecipitated full-length CHK2 (~10 ng) in the presence of 200 μM CaM by radiometric assay. the IC 50 of CHK2 and CaM by Ca 2+ is 30.7 μM. Data represent mean ± SD; n = 3. ( I ) Plot of highest and lowest CHK2 kinase activity from CaCl 2 titration in the presence of 200 μM CaM. individual data points are shown as circles with accompanying mean ± SD; n = 3. Statistical analysis was performed by unpaired t-test; *** P <0.001. ( J ) Schematic of the amino acid residues of recombinant full-length CHK2 and CaM (red) chemically cross-linked by DMTMM (‘zero-length’) and ( K ) photoactivatable cross-linker, NHS-Diazarine (SDA; 3.9 Å spacer), following mass-spectrometry analysis. Cross-links (grey) are only observed within the CHK2 kinase domain (blue) for both chemical cross-linkers. ( L ) Six lysine residues in CHK2, identified by DMTMM chemical cross-linking are mapped to the domain architecture of CHK2. ( M ) Radiometric assay of immunoprecipitated CHK2 wildtype and select cross-linked lysine mutants in the presence (red) or absence (white) of 200 μM CaCl 2 , 1 mM CaM for 10 min. Note: wildtype and K249A kinase-dead data are reproduced from ( C ). Data represent mean ± SD; n = 3. Statistical analysis was performed by two-way ANOVA; * and **** P <0.1 and P <0.0001, respectively; n.s = non-significant. Assay data using recombinant CHK2 kinase domain with each cross-linked lysine mutant are shown in .
    Phospho Chk2 T68, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phospho chk2 t68/product/Proteintech
    Average 95 stars, based on 1 article reviews
    phospho chk2 t68 - by Bioz Stars, 2026-03
    95/100 stars
      Buy from Supplier

    92
    Bioss anti phospho chk2 thr68 rabbit mab
    TGF-β1-induced ROS accumulation leads to G2 arrest through ATM signaling. (A). RT-qPCR analysis of ATM signaling in TGF-β1 and/or its inhibitor-treated PDLSCs; (B). Western blot analysis of ATM signaling in TGF-β1 and/or its inhibitor-treated PDLSCs; (C). Western blot analysis of ATM signaling phosphorylated activation in the condition of ATM or <t>CHK2</t> knockdown; (D). Western blot analysis of ATM signaling phosphorylated activation under N-acetyl-l-cysteine (NAC) treatment; (E). Western blot analysis of ATM signaling phosphorylated activation under decitabine treatment. Reagent doses and duration: TGF-β1 (10 ng/ml, 48 h), NAC (4 mM, 48 h), decitabine (10uM, 48 h). Predicted molecular weight: ATM 350 kDa, pATM 370 kDa, CDC25C&pCDC25C 60 kDa, CHK1&pCHK1 54 kDa, CHK2&pCHK2 62 kDa, β-Tubulin 55 kDa; GAPDH 37 kDa. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, ns denotes not significant by one-way analysis of variance followed by the Tukey’s test. Error bars represent means ± SEM of at least three independent experiments.
    Anti Phospho Chk2 Thr68 Rabbit Mab, supplied by Bioss, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti phospho chk2 thr68 rabbit mab/product/Bioss
    Average 92 stars, based on 1 article reviews
    anti phospho chk2 thr68 rabbit mab - by Bioz Stars, 2026-03
    92/100 stars
      Buy from Supplier

    94
    Bethyl anti phospho chk2 t68
    TGF-β1-induced ROS accumulation leads to G2 arrest through ATM signaling. (A). RT-qPCR analysis of ATM signaling in TGF-β1 and/or its inhibitor-treated PDLSCs; (B). Western blot analysis of ATM signaling in TGF-β1 and/or its inhibitor-treated PDLSCs; (C). Western blot analysis of ATM signaling phosphorylated activation in the condition of ATM or <t>CHK2</t> knockdown; (D). Western blot analysis of ATM signaling phosphorylated activation under N-acetyl-l-cysteine (NAC) treatment; (E). Western blot analysis of ATM signaling phosphorylated activation under decitabine treatment. Reagent doses and duration: TGF-β1 (10 ng/ml, 48 h), NAC (4 mM, 48 h), decitabine (10uM, 48 h). Predicted molecular weight: ATM 350 kDa, pATM 370 kDa, CDC25C&pCDC25C 60 kDa, CHK1&pCHK1 54 kDa, CHK2&pCHK2 62 kDa, β-Tubulin 55 kDa; GAPDH 37 kDa. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, ns denotes not significant by one-way analysis of variance followed by the Tukey’s test. Error bars represent means ± SEM of at least three independent experiments.
    Anti Phospho Chk2 T68, supplied by Bethyl, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti phospho chk2 t68/product/Bethyl
    Average 94 stars, based on 1 article reviews
    anti phospho chk2 t68 - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    96
    Cell Signaling Technology Inc anti phos chk2 t68
    TGF-β1-induced ROS accumulation leads to G2 arrest through ATM signaling. (A). RT-qPCR analysis of ATM signaling in TGF-β1 and/or its inhibitor-treated PDLSCs; (B). Western blot analysis of ATM signaling in TGF-β1 and/or its inhibitor-treated PDLSCs; (C). Western blot analysis of ATM signaling phosphorylated activation in the condition of ATM or <t>CHK2</t> knockdown; (D). Western blot analysis of ATM signaling phosphorylated activation under N-acetyl-l-cysteine (NAC) treatment; (E). Western blot analysis of ATM signaling phosphorylated activation under decitabine treatment. Reagent doses and duration: TGF-β1 (10 ng/ml, 48 h), NAC (4 mM, 48 h), decitabine (10uM, 48 h). Predicted molecular weight: ATM 350 kDa, pATM 370 kDa, CDC25C&pCDC25C 60 kDa, CHK1&pCHK1 54 kDa, CHK2&pCHK2 62 kDa, β-Tubulin 55 kDa; GAPDH 37 kDa. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, ns denotes not significant by one-way analysis of variance followed by the Tukey’s test. Error bars represent means ± SEM of at least three independent experiments.
    Anti Phos Chk2 T68, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti phos chk2 t68/product/Cell Signaling Technology Inc
    Average 96 stars, based on 1 article reviews
    anti phos chk2 t68 - by Bioz Stars, 2026-03
    96/100 stars
      Buy from Supplier

    97
    Cell Signaling Technology Inc anti phospho chk2
    TGF-β1-induced ROS accumulation leads to G2 arrest through ATM signaling. (A). RT-qPCR analysis of ATM signaling in TGF-β1 and/or its inhibitor-treated PDLSCs; (B). Western blot analysis of ATM signaling in TGF-β1 and/or its inhibitor-treated PDLSCs; (C). Western blot analysis of ATM signaling phosphorylated activation in the condition of ATM or <t>CHK2</t> knockdown; (D). Western blot analysis of ATM signaling phosphorylated activation under N-acetyl-l-cysteine (NAC) treatment; (E). Western blot analysis of ATM signaling phosphorylated activation under decitabine treatment. Reagent doses and duration: TGF-β1 (10 ng/ml, 48 h), NAC (4 mM, 48 h), decitabine (10uM, 48 h). Predicted molecular weight: ATM 350 kDa, pATM 370 kDa, CDC25C&pCDC25C 60 kDa, CHK1&pCHK1 54 kDa, CHK2&pCHK2 62 kDa, β-Tubulin 55 kDa; GAPDH 37 kDa. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, ns denotes not significant by one-way analysis of variance followed by the Tukey’s test. Error bars represent means ± SEM of at least three independent experiments.
    Anti Phospho Chk2, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti phospho chk2/product/Cell Signaling Technology Inc
    Average 97 stars, based on 1 article reviews
    anti phospho chk2 - by Bioz Stars, 2026-03
    97/100 stars
      Buy from Supplier

    97
    Cell Signaling Technology Inc c13c1 rabbit mab
    TGF-β1-induced ROS accumulation leads to G2 arrest through ATM signaling. (A). RT-qPCR analysis of ATM signaling in TGF-β1 and/or its inhibitor-treated PDLSCs; (B). Western blot analysis of ATM signaling in TGF-β1 and/or its inhibitor-treated PDLSCs; (C). Western blot analysis of ATM signaling phosphorylated activation in the condition of ATM or <t>CHK2</t> knockdown; (D). Western blot analysis of ATM signaling phosphorylated activation under N-acetyl-l-cysteine (NAC) treatment; (E). Western blot analysis of ATM signaling phosphorylated activation under decitabine treatment. Reagent doses and duration: TGF-β1 (10 ng/ml, 48 h), NAC (4 mM, 48 h), decitabine (10uM, 48 h). Predicted molecular weight: ATM 350 kDa, pATM 370 kDa, CDC25C&pCDC25C 60 kDa, CHK1&pCHK1 54 kDa, CHK2&pCHK2 62 kDa, β-Tubulin 55 kDa; GAPDH 37 kDa. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, ns denotes not significant by one-way analysis of variance followed by the Tukey’s test. Error bars represent means ± SEM of at least three independent experiments.
    C13c1 Rabbit Mab, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/c13c1 rabbit mab/product/Cell Signaling Technology Inc
    Average 97 stars, based on 1 article reviews
    c13c1 rabbit mab - by Bioz Stars, 2026-03
    97/100 stars
      Buy from Supplier

    90
    Affinity Biosciences phospho-chk2 (thr68) rabbit pab antibody
    TGF-β1-induced ROS accumulation leads to G2 arrest through ATM signaling. (A). RT-qPCR analysis of ATM signaling in TGF-β1 and/or its inhibitor-treated PDLSCs; (B). Western blot analysis of ATM signaling in TGF-β1 and/or its inhibitor-treated PDLSCs; (C). Western blot analysis of ATM signaling phosphorylated activation in the condition of ATM or <t>CHK2</t> knockdown; (D). Western blot analysis of ATM signaling phosphorylated activation under N-acetyl-l-cysteine (NAC) treatment; (E). Western blot analysis of ATM signaling phosphorylated activation under decitabine treatment. Reagent doses and duration: TGF-β1 (10 ng/ml, 48 h), NAC (4 mM, 48 h), decitabine (10uM, 48 h). Predicted molecular weight: ATM 350 kDa, pATM 370 kDa, CDC25C&pCDC25C 60 kDa, CHK1&pCHK1 54 kDa, CHK2&pCHK2 62 kDa, β-Tubulin 55 kDa; GAPDH 37 kDa. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, ns denotes not significant by one-way analysis of variance followed by the Tukey’s test. Error bars represent means ± SEM of at least three independent experiments.
    Phospho Chk2 (Thr68) Rabbit Pab Antibody, supplied by Affinity Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/phospho-chk2 (thr68) rabbit pab antibody/product/Affinity Biosciences
    Average 90 stars, based on 1 article reviews
    phospho-chk2 (thr68) rabbit pab antibody - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    Image Search Results


    (A ) Schematic of the conventional mode of Ca 2+ -CaM activation in members of the Ca 2+ -CaM-dependent protein kinase (CaMK) family. Upon Ca 2+ influx, Ca 2+ -CaM binds a linear sequence (CaM-binding sequence; CaMBS; orange) that is proximal to the CaMK kinase domain (blue). This interaction restores activity by sequestering an autoinhibitory pseudosubstrate sequence, which formerly obstructed the active site. ( B ) Far Western blots show that recombinant full-length CHK2 and positive control kinase, CaMKK2, interact with His 6 -CaM in a Ca 2+ -dependent manner (Ca 2+ : 500 μM), as binding is abolished in the presence of the Ca 2+ -chelator, EGTA (10 mM). A negative control pseudokinase, MLKL, did not detectably bind CaM. CaM interaction was detected using an anti-His 6 HRP antibody. data are representative of two independent replicates. ( C ) CHK2 is inhibited by Ca 2+ -CaM. Full-length wildtype and K249A kinase-dead CHK2 were immunoprecipitated and activity was measured by radiometric assay containing 200 μM CHKtide, 200 μM [ 32 P]-γ-ATP and in the presence (red) or absence (white) of 200 μM CaCl 2 , 1 mM CaM for 10 min. Two-way ANOVA; **** P <0.0001; n.s = non-significant. ( D ) Double referenced SPR sensorgrams for immobilised full-length CHK2 binding to analyte, Ca 2+ -CaM. Shown is a representative sensorgram that is colour-coded based on CaM concentration. ( E ) Steady state analysis for the SPR experiment shown in ( D ), along with the dissociation constant. ( F ) Titration of CaM (range 0, 0.5, 1, 2, 5, 10, 20, 50, 100, 200 μM) using immunoprecipitated full-length CHK2 (~10 ng) in the presence of 1 mM CaCl 2 by radiometric assay. The half-maximal inhibitory concentration (IC 50 ) for CaM is 8.1 μM. Data represent mean ± SD; n = 3. ( G ) Plot of highest and lowest CHK2 kinase activity from CaM titration the presence of 1 mM CaCl 2 . Individual data points are shown as circles with accompanying mean ± SD; n = 3. Statistical analysis was performed by unpaired t-test; **** P <0.0001. ( H ) Titration of CaCl 2 (range 0, 1, 2, 5, 10, 20, 50, 100, 200, 500, 1000 μM) using immunoprecipitated full-length CHK2 (~10 ng) in the presence of 200 μM CaM by radiometric assay. the IC 50 of CHK2 and CaM by Ca 2+ is 30.7 μM. Data represent mean ± SD; n = 3. ( I ) Plot of highest and lowest CHK2 kinase activity from CaCl 2 titration in the presence of 200 μM CaM. individual data points are shown as circles with accompanying mean ± SD; n = 3. Statistical analysis was performed by unpaired t-test; *** P <0.001. ( J ) Schematic of the amino acid residues of recombinant full-length CHK2 and CaM (red) chemically cross-linked by DMTMM (‘zero-length’) and ( K ) photoactivatable cross-linker, NHS-Diazarine (SDA; 3.9 Å spacer), following mass-spectrometry analysis. Cross-links (grey) are only observed within the CHK2 kinase domain (blue) for both chemical cross-linkers. ( L ) Six lysine residues in CHK2, identified by DMTMM chemical cross-linking are mapped to the domain architecture of CHK2. ( M ) Radiometric assay of immunoprecipitated CHK2 wildtype and select cross-linked lysine mutants in the presence (red) or absence (white) of 200 μM CaCl 2 , 1 mM CaM for 10 min. Note: wildtype and K249A kinase-dead data are reproduced from ( C ). Data represent mean ± SD; n = 3. Statistical analysis was performed by two-way ANOVA; * and **** P <0.1 and P <0.0001, respectively; n.s = non-significant. Assay data using recombinant CHK2 kinase domain with each cross-linked lysine mutant are shown in .

    Journal: Biochemical Journal

    Article Title: Unconventional binding of calmodulin to CHK2 kinase inhibits catalytic activity

    doi: 10.1042/BCJ20253431

    Figure Lengend Snippet: (A ) Schematic of the conventional mode of Ca 2+ -CaM activation in members of the Ca 2+ -CaM-dependent protein kinase (CaMK) family. Upon Ca 2+ influx, Ca 2+ -CaM binds a linear sequence (CaM-binding sequence; CaMBS; orange) that is proximal to the CaMK kinase domain (blue). This interaction restores activity by sequestering an autoinhibitory pseudosubstrate sequence, which formerly obstructed the active site. ( B ) Far Western blots show that recombinant full-length CHK2 and positive control kinase, CaMKK2, interact with His 6 -CaM in a Ca 2+ -dependent manner (Ca 2+ : 500 μM), as binding is abolished in the presence of the Ca 2+ -chelator, EGTA (10 mM). A negative control pseudokinase, MLKL, did not detectably bind CaM. CaM interaction was detected using an anti-His 6 HRP antibody. data are representative of two independent replicates. ( C ) CHK2 is inhibited by Ca 2+ -CaM. Full-length wildtype and K249A kinase-dead CHK2 were immunoprecipitated and activity was measured by radiometric assay containing 200 μM CHKtide, 200 μM [ 32 P]-γ-ATP and in the presence (red) or absence (white) of 200 μM CaCl 2 , 1 mM CaM for 10 min. Two-way ANOVA; **** P <0.0001; n.s = non-significant. ( D ) Double referenced SPR sensorgrams for immobilised full-length CHK2 binding to analyte, Ca 2+ -CaM. Shown is a representative sensorgram that is colour-coded based on CaM concentration. ( E ) Steady state analysis for the SPR experiment shown in ( D ), along with the dissociation constant. ( F ) Titration of CaM (range 0, 0.5, 1, 2, 5, 10, 20, 50, 100, 200 μM) using immunoprecipitated full-length CHK2 (~10 ng) in the presence of 1 mM CaCl 2 by radiometric assay. The half-maximal inhibitory concentration (IC 50 ) for CaM is 8.1 μM. Data represent mean ± SD; n = 3. ( G ) Plot of highest and lowest CHK2 kinase activity from CaM titration the presence of 1 mM CaCl 2 . Individual data points are shown as circles with accompanying mean ± SD; n = 3. Statistical analysis was performed by unpaired t-test; **** P <0.0001. ( H ) Titration of CaCl 2 (range 0, 1, 2, 5, 10, 20, 50, 100, 200, 500, 1000 μM) using immunoprecipitated full-length CHK2 (~10 ng) in the presence of 200 μM CaM by radiometric assay. the IC 50 of CHK2 and CaM by Ca 2+ is 30.7 μM. Data represent mean ± SD; n = 3. ( I ) Plot of highest and lowest CHK2 kinase activity from CaCl 2 titration in the presence of 200 μM CaM. individual data points are shown as circles with accompanying mean ± SD; n = 3. Statistical analysis was performed by unpaired t-test; *** P <0.001. ( J ) Schematic of the amino acid residues of recombinant full-length CHK2 and CaM (red) chemically cross-linked by DMTMM (‘zero-length’) and ( K ) photoactivatable cross-linker, NHS-Diazarine (SDA; 3.9 Å spacer), following mass-spectrometry analysis. Cross-links (grey) are only observed within the CHK2 kinase domain (blue) for both chemical cross-linkers. ( L ) Six lysine residues in CHK2, identified by DMTMM chemical cross-linking are mapped to the domain architecture of CHK2. ( M ) Radiometric assay of immunoprecipitated CHK2 wildtype and select cross-linked lysine mutants in the presence (red) or absence (white) of 200 μM CaCl 2 , 1 mM CaM for 10 min. Note: wildtype and K249A kinase-dead data are reproduced from ( C ). Data represent mean ± SD; n = 3. Statistical analysis was performed by two-way ANOVA; * and **** P <0.1 and P <0.0001, respectively; n.s = non-significant. Assay data using recombinant CHK2 kinase domain with each cross-linked lysine mutant are shown in .

    Article Snippet: Primary antibodies used in this study for immunoblotting were: rabbit anti-His 6 -HRP-conjugated (Abcam; clone ab1187: 1:5000); rat anti-FLAG (WEHI clone 9H1; produced in-house; 1:1000); rabbit anti-phospho-Thr383 CHK2 (ThermoFisher; catalog PA5-104714; 1:1000); mouse anti-CHK2 (Cell Signaling Technology; clone 1C12; 1:1000); mouse anti-actin, (Sigma-Aldrich, A-1978; 1:1000).

    Techniques: Activation Assay, Sequencing, Binding Assay, Activity Assay, Western Blot, Recombinant, Positive Control, Negative Control, Immunoprecipitation, Concentration Assay, Titration, Mass Spectrometry, Mutagenesis

    (A ) Quantitative analysis of deuterium exchange differences of human CHK2 in the presence of Ca 2+ -CaM, following hydrogen-deuterium exchange mass spectrometry (HDX-MS). The graph shows the #D difference in deuterium incorporation for CHK2 over the entire time course. Each point represents an individual peptide, with those coloured in red showing a significant change (greater than 0.40 Da and 5% difference at any timepoint, with a two tailed t -test; P <0.01, n = 3), with error bars showing standard deviation. CHK2 domain architecture is annotated above. ( B ) Significant differences in deuterium exchange are mapped onto an AlphaFold3 model of CHK2 and are colour-coded according to the legend. Zoomed view of the CHK2 active site cleft is shown on the right. Key catalytic residues and cross-linked lysine residues (from <xref ref-type=Figure 1L ) are annotated. ( C ) Cross-linking mass spectrometry data are mapped onto an AlphaFold model of CaM:CHK2. ‘Zero-length’ DMTMM and SDA cross-links are shown in red and blue, respectively. Key catalytic residues of CHK2 are shown in yellow. ( D ) The electrostatic potential mapped onto the molecular surface of CHK2 reveals patches of positive charge that are proximal with residues in ( C ) and complement the negatively charged surface of CaM. ( E ) AlphaFold3 model of human CHK2 kinase domain (blue) in complex with CaM (red). " width="100%" height="100%">

    Journal: Biochemical Journal

    Article Title: Unconventional binding of calmodulin to CHK2 kinase inhibits catalytic activity

    doi: 10.1042/BCJ20253431

    Figure Lengend Snippet: (A ) Quantitative analysis of deuterium exchange differences of human CHK2 in the presence of Ca 2+ -CaM, following hydrogen-deuterium exchange mass spectrometry (HDX-MS). The graph shows the #D difference in deuterium incorporation for CHK2 over the entire time course. Each point represents an individual peptide, with those coloured in red showing a significant change (greater than 0.40 Da and 5% difference at any timepoint, with a two tailed t -test; P <0.01, n = 3), with error bars showing standard deviation. CHK2 domain architecture is annotated above. ( B ) Significant differences in deuterium exchange are mapped onto an AlphaFold3 model of CHK2 and are colour-coded according to the legend. Zoomed view of the CHK2 active site cleft is shown on the right. Key catalytic residues and cross-linked lysine residues (from Figure 1L ) are annotated. ( C ) Cross-linking mass spectrometry data are mapped onto an AlphaFold model of CaM:CHK2. ‘Zero-length’ DMTMM and SDA cross-links are shown in red and blue, respectively. Key catalytic residues of CHK2 are shown in yellow. ( D ) The electrostatic potential mapped onto the molecular surface of CHK2 reveals patches of positive charge that are proximal with residues in ( C ) and complement the negatively charged surface of CaM. ( E ) AlphaFold3 model of human CHK2 kinase domain (blue) in complex with CaM (red).

    Article Snippet: Primary antibodies used in this study for immunoblotting were: rabbit anti-His 6 -HRP-conjugated (Abcam; clone ab1187: 1:5000); rat anti-FLAG (WEHI clone 9H1; produced in-house; 1:1000); rabbit anti-phospho-Thr383 CHK2 (ThermoFisher; catalog PA5-104714; 1:1000); mouse anti-CHK2 (Cell Signaling Technology; clone 1C12; 1:1000); mouse anti-actin, (Sigma-Aldrich, A-1978; 1:1000).

    Techniques: Mass Spectrometry, Two Tailed Test, Standard Deviation, Structural Proteomics

    (A ) Multiple sequence alignment of CHK2 orthologs, which highlights the conservation of CHK2 residues in animals and fungi (K255, K373 and K465; asterisk) implicated in interaction with Ca 2+ -CaM. Residues in the alignment are coloured according to the Clustal colouring scheme, which highlights chemical nature and patterns of conservation. ( B ) Chromatograms from Sanger sequencing confirm the successful integration of nucleotide changes for K373A in hTERT-immortalized RPE cells by CRISPR/Cas9. ( C ) Real-time proliferation analysis of wildtype and CRISPR-edited RPE cells using IncuCyte live-cell imaging, and ( D ) corresponding area under the curve. Data represent mean ± SD; n = 8. Statistical analysis was performed by paired t -test; **** P <0.0001. ( E ) Real-time proliferation analysis of wildtype and CRISPR-edited RPE cells cultured in the presence of DNA damaging agent, camptothecin (CPT), at 10 nM and 100 nM, and ( F ) corresponding area under the curve. Data represent mean ± SD; n = 8. Statistical analysis was performed by two-way ANOVA; **** P <0.0001. ( G ) Raw micrographs of cell confluence exported from the IncuCyte SX3 system after 72 h incubation; the scale bars (black) represent 100 µm. ( H ) Whole cell-lysates of hTERT-immortalised RPE cells (wildtype and CHK2 K373A ) were resolved by SDS-PAGE and probed by immunoblot for phospho-CHK2 (Thr383) and total CHK2 with anti-actin as a loading control. Immunoblots are representative of n = 2 independent experiments.

    Journal: Biochemical Journal

    Article Title: Unconventional binding of calmodulin to CHK2 kinase inhibits catalytic activity

    doi: 10.1042/BCJ20253431

    Figure Lengend Snippet: (A ) Multiple sequence alignment of CHK2 orthologs, which highlights the conservation of CHK2 residues in animals and fungi (K255, K373 and K465; asterisk) implicated in interaction with Ca 2+ -CaM. Residues in the alignment are coloured according to the Clustal colouring scheme, which highlights chemical nature and patterns of conservation. ( B ) Chromatograms from Sanger sequencing confirm the successful integration of nucleotide changes for K373A in hTERT-immortalized RPE cells by CRISPR/Cas9. ( C ) Real-time proliferation analysis of wildtype and CRISPR-edited RPE cells using IncuCyte live-cell imaging, and ( D ) corresponding area under the curve. Data represent mean ± SD; n = 8. Statistical analysis was performed by paired t -test; **** P <0.0001. ( E ) Real-time proliferation analysis of wildtype and CRISPR-edited RPE cells cultured in the presence of DNA damaging agent, camptothecin (CPT), at 10 nM and 100 nM, and ( F ) corresponding area under the curve. Data represent mean ± SD; n = 8. Statistical analysis was performed by two-way ANOVA; **** P <0.0001. ( G ) Raw micrographs of cell confluence exported from the IncuCyte SX3 system after 72 h incubation; the scale bars (black) represent 100 µm. ( H ) Whole cell-lysates of hTERT-immortalised RPE cells (wildtype and CHK2 K373A ) were resolved by SDS-PAGE and probed by immunoblot for phospho-CHK2 (Thr383) and total CHK2 with anti-actin as a loading control. Immunoblots are representative of n = 2 independent experiments.

    Article Snippet: Primary antibodies used in this study for immunoblotting were: rabbit anti-His 6 -HRP-conjugated (Abcam; clone ab1187: 1:5000); rat anti-FLAG (WEHI clone 9H1; produced in-house; 1:1000); rabbit anti-phospho-Thr383 CHK2 (ThermoFisher; catalog PA5-104714; 1:1000); mouse anti-CHK2 (Cell Signaling Technology; clone 1C12; 1:1000); mouse anti-actin, (Sigma-Aldrich, A-1978; 1:1000).

    Techniques: Sequencing, CRISPR, Live Cell Imaging, Cell Culture, Incubation, SDS Page, Western Blot, Control

    Following DNA damage, the upstream kinase, ATM (green), phosphorylates Thr68 within the CHK2 SCD, which leads to the formation of a transient homodimer, mediated by the CHK2 FHA domains binding to pThr68. This dimerization results in CHK2 activation loop phosphorylation on T383 in trans and increased catalytic activity. Following activation, CHK2 phosphorylates multiple substrates, including CDC25C, BRCA1, HDMX, PLK1 and TP53, to promote cell cycle arrest and impede DNA repair. Upon sensing increased Ca 2+ levels, CaM can directly interact with the CHK2 kinase domain to inhibit catalytic activity and enable cell cycle progression and DNA repair.

    Journal: Biochemical Journal

    Article Title: Unconventional binding of calmodulin to CHK2 kinase inhibits catalytic activity

    doi: 10.1042/BCJ20253431

    Figure Lengend Snippet: Following DNA damage, the upstream kinase, ATM (green), phosphorylates Thr68 within the CHK2 SCD, which leads to the formation of a transient homodimer, mediated by the CHK2 FHA domains binding to pThr68. This dimerization results in CHK2 activation loop phosphorylation on T383 in trans and increased catalytic activity. Following activation, CHK2 phosphorylates multiple substrates, including CDC25C, BRCA1, HDMX, PLK1 and TP53, to promote cell cycle arrest and impede DNA repair. Upon sensing increased Ca 2+ levels, CaM can directly interact with the CHK2 kinase domain to inhibit catalytic activity and enable cell cycle progression and DNA repair.

    Article Snippet: Primary antibodies used in this study for immunoblotting were: rabbit anti-His 6 -HRP-conjugated (Abcam; clone ab1187: 1:5000); rat anti-FLAG (WEHI clone 9H1; produced in-house; 1:1000); rabbit anti-phospho-Thr383 CHK2 (ThermoFisher; catalog PA5-104714; 1:1000); mouse anti-CHK2 (Cell Signaling Technology; clone 1C12; 1:1000); mouse anti-actin, (Sigma-Aldrich, A-1978; 1:1000).

    Techniques: Binding Assay, Activation Assay, Phospho-proteomics, Activity Assay

    (A ) Ca 2+ -CaM-dependent protein kinase II (PDB 2WEL) ; ( B ) Death-associated protein kinases (DAPK)-1 (PDB 2X0G) ; and ( C ) DAPK2 (PDB 6PAW) harbor a conventional CaM-binding sequence C-terminal to the protein kinase domain. ( D ) GPCR kinase 5 (GRK5; PDB 6PJX) interacts with Ca 2+ -CaM via two helical regions N- and C-terminal to the protein kinase domain. ( E ) Ca 2+ -CaM directly interacts with the protein kinase domain of CHK2 (AlphaFold model; from this study). Each mode of Ca 2+ -CaM regulation is illustrated in a Richardson (ribbons) diagram (top panel) and schematic representation (lower panel). The protein kinase domain is coloured blue, while other domains are grey. CaM and CaM-binding sequences (CaMBS) are coloured red and orange, respectively. Ca 2+ ions are coloured yellow.

    Journal: Biochemical Journal

    Article Title: Unconventional binding of calmodulin to CHK2 kinase inhibits catalytic activity

    doi: 10.1042/BCJ20253431

    Figure Lengend Snippet: (A ) Ca 2+ -CaM-dependent protein kinase II (PDB 2WEL) ; ( B ) Death-associated protein kinases (DAPK)-1 (PDB 2X0G) ; and ( C ) DAPK2 (PDB 6PAW) harbor a conventional CaM-binding sequence C-terminal to the protein kinase domain. ( D ) GPCR kinase 5 (GRK5; PDB 6PJX) interacts with Ca 2+ -CaM via two helical regions N- and C-terminal to the protein kinase domain. ( E ) Ca 2+ -CaM directly interacts with the protein kinase domain of CHK2 (AlphaFold model; from this study). Each mode of Ca 2+ -CaM regulation is illustrated in a Richardson (ribbons) diagram (top panel) and schematic representation (lower panel). The protein kinase domain is coloured blue, while other domains are grey. CaM and CaM-binding sequences (CaMBS) are coloured red and orange, respectively. Ca 2+ ions are coloured yellow.

    Article Snippet: Primary antibodies used in this study for immunoblotting were: rabbit anti-His 6 -HRP-conjugated (Abcam; clone ab1187: 1:5000); rat anti-FLAG (WEHI clone 9H1; produced in-house; 1:1000); rabbit anti-phospho-Thr383 CHK2 (ThermoFisher; catalog PA5-104714; 1:1000); mouse anti-CHK2 (Cell Signaling Technology; clone 1C12; 1:1000); mouse anti-actin, (Sigma-Aldrich, A-1978; 1:1000).

    Techniques: Binding Assay, Sequencing

    TGF-β1-induced ROS accumulation leads to G2 arrest through ATM signaling. (A). RT-qPCR analysis of ATM signaling in TGF-β1 and/or its inhibitor-treated PDLSCs; (B). Western blot analysis of ATM signaling in TGF-β1 and/or its inhibitor-treated PDLSCs; (C). Western blot analysis of ATM signaling phosphorylated activation in the condition of ATM or CHK2 knockdown; (D). Western blot analysis of ATM signaling phosphorylated activation under N-acetyl-l-cysteine (NAC) treatment; (E). Western blot analysis of ATM signaling phosphorylated activation under decitabine treatment. Reagent doses and duration: TGF-β1 (10 ng/ml, 48 h), NAC (4 mM, 48 h), decitabine (10uM, 48 h). Predicted molecular weight: ATM 350 kDa, pATM 370 kDa, CDC25C&pCDC25C 60 kDa, CHK1&pCHK1 54 kDa, CHK2&pCHK2 62 kDa, β-Tubulin 55 kDa; GAPDH 37 kDa. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, ns denotes not significant by one-way analysis of variance followed by the Tukey’s test. Error bars represent means ± SEM of at least three independent experiments.

    Journal: Journal of Advanced Research

    Article Title: Multi-omics approach reveals TGF-β signaling-driven senescence in periodontium stem cells

    doi: 10.1016/j.jare.2024.12.037

    Figure Lengend Snippet: TGF-β1-induced ROS accumulation leads to G2 arrest through ATM signaling. (A). RT-qPCR analysis of ATM signaling in TGF-β1 and/or its inhibitor-treated PDLSCs; (B). Western blot analysis of ATM signaling in TGF-β1 and/or its inhibitor-treated PDLSCs; (C). Western blot analysis of ATM signaling phosphorylated activation in the condition of ATM or CHK2 knockdown; (D). Western blot analysis of ATM signaling phosphorylated activation under N-acetyl-l-cysteine (NAC) treatment; (E). Western blot analysis of ATM signaling phosphorylated activation under decitabine treatment. Reagent doses and duration: TGF-β1 (10 ng/ml, 48 h), NAC (4 mM, 48 h), decitabine (10uM, 48 h). Predicted molecular weight: ATM 350 kDa, pATM 370 kDa, CDC25C&pCDC25C 60 kDa, CHK1&pCHK1 54 kDa, CHK2&pCHK2 62 kDa, β-Tubulin 55 kDa; GAPDH 37 kDa. Statistical significance: * p < 0.05, ** p < 0.01, *** p < 0.001, ns denotes not significant by one-way analysis of variance followed by the Tukey’s test. Error bars represent means ± SEM of at least three independent experiments.

    Article Snippet: Antibodies used in this study were listed as follows: antibodies from Abmart: anti-β-Tubulin ( M20005 ); antibodies from Huabio: anti-GAPDH recombinant rabbit monoclonal antibody (ET1601-4), anti-DNMT1 recombinant rabbit monoclonal antibody (ET1702-77), anti-DNMT3A recombinant rabbit monoclonal antibody (ET1609-31), anti-DNMT3B recombinant rabbit monoclonal antibody (ET1605-9), anti-p16 INK4A recombinant rabbit monoclonal antibody (ET1608-62), anti-AMPKγ1 recombinant mouse monoclonal antibody (EM2001-06), anti-AMPK alpha 1 recombinant rabbit monoclonal antibody (ET1608-40), anti-phospho-AMPK alpha 1 (S496) recombinant rabbit monoclonal antibody (ET1612-72), HRP-conjugated goat anti-rabbit IgG goat polyclonal antibody (HA1001), HRP-conjugated goat anti-mouse IgG polyclonal antibody (HA1006); antibodies from Abcam: anti-ATM antibody (ab32420), anti-phospho-ATM (S1981) antibody (ab81292), anti-CHK1 antibody (ab40866), anti-phospho-CHK1 (S296) antibody (ab79758), anti-CDC25C antibody (ab32444), anti-p21 antibody (ab109199), anti-CHK2 antibody (ab109413), anti-histone H3 (tri-methyl K9) (ab176916), anti-phospho-γ-H2AX (S139) antibody (ab81299), anti-HMGB1 antibody (ab79823); antibodies from CST: anti-Ki67 (D3B5) rabbit mAb (#9129), anti-phospho-CHK2 (Thr68) rabbit mAb (#2197), anti-phospho-CDC25C (Ser216) rabbit mAb (#4901); antibodies from Bioss: goat anti-rabbit IgG antibody (H + L), FITC-conjugated (bs-0295G-FITC); goat anti-rat IgG antibody (H + L), cyanine 3-conjugated (bs-0293G-Cy3); antibodies from Biolegend: APC anti-human CD34 antibody (#343509), FITC anti-human CD146 antibody (#361011).

    Techniques: Quantitative RT-PCR, Western Blot, Activation Assay, Knockdown, Molecular Weight